Log In Sign Up

Unlisted Shares

IPO & Startups

Mutual Funds

PMS

Listed

Analyse

Track

ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel
HDFC Pharma and Healthcare Fund - Regular Plan - Growth
Equity Sector Funds Very High Risk Fund Manager: Nikhil Mathur

My Notes

No Notes Added Yet

📓 Notes
16.65%
1Y Return
-1.30% 1D
Overview Returns Historical Holdings Peer Comparison Fund Managers AMC FAQ
Latest NAV
₹20.22
Fund Size
₹3,501 Cr
Turnover Ratio
35.64
Lock-in Period
Nil
Inception Date
04 Oct 2023
Return Since Inception
26.16%
Fund Type
Open ended scheme
Min. Lumpsum / SIP
₹100 / ₹100

To provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies.

Looking to Grow Your Wealth with Mutual Funds?

Expert-managed portfolios tailored to your financial goals and risk appetite.

NAV Performance
Historical Net Asset Value
16.65% 1Y Return
≤ 1 year — Absolute; > 1 year — CAGR
Return Calculator
Estimation based on past performance
Monthly Investment
₹
Over The Past
Invested Amount
0
Est. Returns
0
After 0 Years your investment will be:
₹ 0 (0%)
Lumpsum Investment
₹
Over The Past
Invested Amount
0
Est. Returns
0
After 0 Years your investment will be:
₹ 0 (0%)
Returns and Rankings
Benchmark: BSE Health Care - TRI
Sector Funds 1M3M6M9M1Y 2Y3Y4Y5Y10YALL
Fund returns -8.18%-2.85% 13.49%19.65% 16.65%11.44% 26.3%N/A N/AN/A 26.16%
Category returns -7.54%-3.42% 10.54%13.4% 8.01%3.9% 18.22%18.48% 12.78%13.01% N/A
Absolute returns -8.18%-2.85%13.49%19.65%16.65%24.23%101.61%N/AN/AN/A 102.86%
Rank within category 16/19 8/18 4/18 2/18 1/17 1/14 1/12 N/A N/A N/A N/A
≤ 1 year — Absolute; > 1 year — CAGR
Historical Data
Benchmark: BSE Health Care - TRI
Sector Funds 2023202420252026
Yearly returnsN/A50.33%1.22%17.32%
Q1 returnsN/A8.5%-6.47%-1.46%
Q2 returnsN/A6.75%5.72%20.16%
Q3 returnsN/A23.01%-0.42%3.82%
Q4 returnsN/A5.51%2.8%-4.56%
Expense Ratio, Exit Load & Tax
Expense Ratio: 2.11% (Inclusive of GST)
Exit Load

1% on or before 30D, Nil after 30D

Advanced Ratios
Alpha1.7444
Beta0.5917
Sharpe Ratio0.446068
Sortino Ratio0.96624
Risk Metrics
R-Squared0.2731
Tracking Error3.7688
Downside Risk15.1336
Std. Deviation (Annualised)14.1061
Peer Comparison
Sector Funds 1M3M6M9M1Y3Y5Y10YALL Fund Size (Cr)Exp. RatioSharpeRisk
HDFC Pharma and Healthcare Fund - Regular Plan - Growth Current -8.18% -2.85% 13.49% 19.65% 16.65% 26.3% N/A N/A 26.16% 3,501.37 2.11 0.45 Very High
SBI Healthcare Opportunities Fund - Regular Plan - IDCW -7.91% -3.95% 12% 16.9% 9.98% 20.31% 16% 12.88% 16.36% 5,870.00 1.99 0.33 Very High
UTI Healthcare Fund - Regular Plan - IDCW -8.04% -4.49% 10.8% 14.7% 7.94% 19.65% 13.41% 12.86% 14.71% 1,429.84 2.22 0.32 Very High
Mirae Asset Healthcare Fund - Regular Plan - Growth -6.65% -2.37% 10.95% 15.8% 10.86% 19.1% 13.11% N/A 19.31% 3,494.44 2.04 0.30 Very High
ICICI Prudential Healthcare Fund - Growth -5.27% -5.77% 5.31% 6.11% 1.04% 18.9% 14.21% N/A 18.53% 6,861.20 2.08 0.30 Very High
LIC MF Healthcare Fund - Regular Plan - Growth -8.31% -3.16% 10.44% 10.22% 4.45% 18.2% 9.97% N/A 16.14% 99.36 2.67 0.28 Very High
DSP Healthcare Fund - Regular Plan - Growth -5.87% -2.13% 13.11% 11.93% 9.74% 17.47% 13.29% N/A 20.34% 3,750.04 2.05 0.29 Very High
Aditya Birla Sun Life Pharma & Healthcare Fund - Regular Plan - Growth -7.92% -5.04% 8.82% 11.15% 7.84% 16.89% 11.54% N/A 18.16% 1,077.52 2.29 0.27 Very High
Quant Healthcare Fund - Regular Plan - Growth -7.41% -1.49% 10.61% 18.21% 9.71% 16.57% N/A N/A 17.69% 424.53 3.13 0.23 Very High
Tata India Pharma & Healthcare Fund - Regular Plan - Growth -7.42% -6.38% 5.15% 4.71% -0.23% 15.22% 11.84% 12.5% 11% 1,511.49 2.37 0.23 Very High
Holdings (40)
Instrument Type
Domestic Equities
96.77%
Cash & Cash Equivalents and Net Assets
3.23%
Sector
Pharmaceuticals & Biotechnology
71.26%
Others
3.23%
Healthcare Services
22.13%
Healthcare Equipment & Supplies
2.36%
Retailing
1.01%
NameSectorInstrumentAssets %
Divi's Laboratories Ltd. Pharmaceuticals & Biotechnology Domestic Equities 9.39%
Sun Pharmaceutical Industries Ltd. Pharmaceuticals & Biotechnology Domestic Equities 8.28%
TREPS - Tri-party Repo Cash & Cash Equivalents and Net Assets 4.67%
Alkem Laboratories Ltd. Pharmaceuticals & Biotechnology Domestic Equities 4.64%
Cipla Ltd. Pharmaceuticals & Biotechnology Domestic Equities 4.15%
Apollo Hospitals Enterprise Ltd. Healthcare Services Domestic Equities 3.69%
Torrent Pharmaceuticals Ltd. Pharmaceuticals & Biotechnology Domestic Equities 3.65%
Max Healthcare Institute Ltd. Healthcare Services Domestic Equities 3.61%
Aster DM Quality Care Ltd. Healthcare Services Domestic Equities 3.56%
Lupin Ltd. Pharmaceuticals & Biotechnology Domestic Equities 3.55%
Neuland Laboratories Ltd. Pharmaceuticals & Biotechnology Domestic Equities 3.24%
Shilpa Medicare Ltd. Pharmaceuticals & Biotechnology Domestic Equities 3.23%
Dr. Reddy's Laboratories Ltd. Pharmaceuticals & Biotechnology Domestic Equities 3.19%
Acutaas Chemicals Ltd. Pharmaceuticals & Biotechnology Domestic Equities 3.18%
Anthem Biosciences Ltd. Pharmaceuticals & Biotechnology Domestic Equities 3.17%
Ipca Laboratories Ltd. Pharmaceuticals & Biotechnology Domestic Equities 2.98%
Global Health Ltd. Healthcare Services Domestic Equities 2.72%
Rubicon Research Ltd. Pharmaceuticals & Biotechnology Domestic Equities 2.52%
Krishna Institute of Medical Sciences Ltd Healthcare Services Domestic Equities 2.10%
Glenmark Pharmaceuticals Ltd. Pharmaceuticals & Biotechnology Domestic Equities 2.09%
Molbio Diagnostics Ltd. Healthcare Equipment & Supplies Domestic Equities 2.01%
Vijaya Diagnostic Centre Ltd. Healthcare Services Domestic Equities 2.00%
Zydus Lifesciences Ltd. Pharmaceuticals & Biotechnology Domestic Equities 1.82%
Gland Pharma Ltd. Pharmaceuticals & Biotechnology Domestic Equities 1.78%
Wockhardt Ltd. Pharmaceuticals & Biotechnology Domestic Equities 1.71%
Jupiter Life Line Hospitals Ltd. Healthcare Services Domestic Equities 1.68%
Metropolis Healthcare Ltd. Healthcare Services Domestic Equities 1.67%
Sai Life Sciences Ltd. Pharmaceuticals & Biotechnology Domestic Equities 1.58%
Biocon Ltd. Pharmaceuticals & Biotechnology Domestic Equities 1.47%
Symbiotec Pharmalab Ltd. Pharmaceuticals & Biotechnology Domestic Equities 1.36%
Thyrocare Technologies Ltd. Healthcare Services Domestic Equities 1.10%
CORONA Remedies Ltd. Pharmaceuticals & Biotechnology Domestic Equities 1.04%
Entero Healthcare Solutions Ltd. Retailing Domestic Equities 1.01%
Jubilant Pharmova Ltd. Pharmaceuticals & Biotechnology Domestic Equities 0.93%
Eris Lifesciences Ltd. Pharmaceuticals & Biotechnology Domestic Equities 0.92%
Evonile Pharma Ltd. Pharmaceuticals & Biotechnology Domestic Equities 0.55%
Bajaj Healthcare Ltd. Pharmaceuticals & Biotechnology Domestic Equities 0.53%
Laxmi Dental Ltd. Healthcare Equipment & Supplies Domestic Equities 0.35%
Cohance Lifesciences Ltd. Pharmaceuticals & Biotechnology Domestic Equities 0.32%
Net Current Assets Cash & Cash Equivalents and Net Assets -1.44%
Total100.00%
FUND MANAGERS
Managed By Experts
MN
Mr. Nikhil Mathur
in

Over 7 years of experience in equity research and 2 years in financial advisory.

Age
35 Yrs
Experience
7 Years
Reported
14 Sep 2023
PGDM - IMT, B.E. (Civil), CFA (USA)
FAQ
All You Need To Know About Mutual Funds
It is an Open ended scheme that primarily invests in Sector Funds.
To provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies.
The scheme benchmark is the BSE Health Care - TRI.
It is classified as Very High Risk.
1-year: 16.65% | 3-year: 26.3% | 5-year: N/A (scheme is younger than 5 years)
Top holdings include: Divi's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., TREPS - Tri-party Repo, Alkem Laboratories Ltd., Cipla Ltd.
The NAV is around ₹20.22.
The fund's AUM is approximately ₹3,501 Cr.
The expense ratio for the Regular Plan is 2.11%.
1% on or before 30D, Nil after 30D.
Minimum SIP starts at ₹100.
The minimum lump sum investment is ₹100.
You can start a SIP through the Sharescart platform. Enter KYC details, choose the Regular Growth option, set SIP amount and frequency, and submit.
The fund manager: Nikhil Mathur
This fund is suitable for investors with a Very High risk tolerance.
📈

Looking to Grow Your Wealth with Mutual Funds?

Get personalized portfolio management services designed to grow and protect your wealth.

Search for mutual funds here

×
Loading scheme details...

Place Order

HDFC Pharma and Healthcare Fund - Regular Plan - Growth
Very High Risk | Sector Funds | Equity
UCC
FIRST HOLDER
₹
Minimum SIP Amount: ₹100
SIP Duration
End date will follow selected start date day.
Maximum installment option selected.
By clicking on Place Order, I confirm that I have read all the Scheme Information Document.
whatsapp

Error!

View quotes